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Abstract
Background: Viral bronchiolitis is the leading cause of hospitalization in young infants. It is associated with the 
development of childhood asthma and contributes to morbidity and mortality in the elderly. Currently no therapies 
effectively attenuate inflammation during the acute viral infection, or prevent the risk of post-viral asthma. We 
hypothesized that early treatment of a paramyxoviral bronchiolitis with azithromycin would attenuate acute and 
chronic airway inflammation.
Methods: Mice were inoculated with parainfluenza type 1, Sendai Virus (SeV), and treated daily with PBS or 
azithromycin for 7 days post-inoculation. On day 8 and 21 we assessed airway inflammation in lung tissue, and 
quantified immune cells and inflammatory mediators in bronchoalveolar lavage (BAL).
Results: Compared to treatment with PBS, azithromycin significantly attenuated post-viral weight loss. During the peak 
of acute inflammation (day 8), azithromycin decreased total leukocyte accumulation in the lung tissue and BAL, with 
the largest fold-reduction in BAL neutrophils. This decreased inflammation was independent of changes in viral load. 
Azithromycin significantly attenuated the concentration of BAL inflammatory mediators and enhanced resolution of 
chronic airway inflammation evident by decreased BAL inflammatory mediators on day 21.
Conclusions: In this mouse model of paramyxoviral bronchiolitis, azithromycin attenuated acute and chronic airway 
inflammation. These findings demonstrate anti-inflammatory effects of azithromycin that are not related to anti-viral 
activity. Our findings support the rationale for future prospective randomized clinical trials that will evaluate the effects 
of macrolides on acute viral bronchiolitis and their long-term consequences.
Background
Viral bronchiolitis is the most common acute infection of
the lower respiratory tract in infancy, and is most often
caused by the paramyxoviruses, especially respiratory
syncytial virus (RSV). RSV will infect 95% of children by
the age of 2 [1], and up to 3% of infected children will
develop a severe bronchiolitis requiring hospitalization
[ 2 ] .  T h e  r a t e  o f  a d m i s s i o n s  h a s  d o u b l e d  i n  t h e  p a s t  2
decades [3]; as a result, severe RSV bronchiolitis is now
the leading cause of hospitalization in infants younger the
age of 1 year [4]. Chronic respiratory symptoms are com-
mon after severe RSV bronchiolitis, with about 40% of
hospitalized children eventually developing asthma [5-8].
The development of asthma following RSV infection
appears to be related to the severity of the initial infection
[9]. RSV infection is not limited to children and contrib-
utes significantly to morbidity and mortality in the elderly
population [10]. These findings suggest that attenuating
the acute viral infection may be an effective strategy to
attenuate the acute and long-term consequences of viral
bronchiolitis.
No specific therapies are currently recommended for
severe RSV bronchiolitis [11]. Ideally a beneficial phar-
macologic agent would reduce acute morbidity as well as
modify the anti-viral host response to avert the subse-
quent development of asthma. One class of potentially
useful therapeutic agents is the macrolide antibiotics,
since they possess distinct anti-inflammatory properties
in addition to their antimicrobial effects [12-25]. Two
clinical studies have evaluated macrolide treatment dur-
ing severe RSV bronchiolitis in children, but these studies
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have yielded conflicting results [26,27]. Therefore, defini-
tive conclusions regarding the usefulness of macrolides as
a treatment of viral-bronchiolitis cannot be made at this
time.
To examine the anti-inflammatory properties of mac-
rolides in a high fidelity animal model of human RSV
bronchiolitis, we tested the ability of azithromycin to
modulate a well-characterized viral bronchiolitis model
using a mouse parainfluenza type I virus, referred to as
Sendai virus (SeV) [28,29]. SeV replicates at high effi-
ciency in the mouse lung and results in an acute viral
bronchiolitis, and chronic airway inflammation that per-
sists for at least one year following viral inoculation
[28,29]. We hypothesized that treatment of mouse SeV
bronchiolitis with azithromycin during the acute infec-
tion would attenuate early airway inflammation, and also
decrease the chronic post-viral pathologic abnormalities,
such as immune cell accumulation and the mediators that
drive these processes.
Materials and methods
Mice
C57BL/6J female mice were purchased from the Jackson
La bora t o ry (Ba r H ar bor , M E) .  All  m ic e  w e r e  br ed and
housed under specific pathogen-free conditions at Wash-
ington University School of Medicine where sentinel
mice (pathogen free ICN-strain) exhibited no serologic or
histologic evidence of exposure to 15 murine pathogens
(including SeV). Before performing these in vivo experi-
ments, we investigated whether our colony of mice were
actively infected or colonized with bacteria in the trachea
and lungs. We obtained tracheal swabs and tissue sam-
ples from both lungs, from 5 mice, and plated them on
tryptic soy agar plates supplemented with 5% sheep
blood, incubated for 48 hours at 37°C and no colonies
were identified. T o determine if our colony of mice had
serologic evidence of prior Mycoplasma pulmonis expo-
sure, serum was collected for indirect ELISA using Myco-
plasma pulmonis antigen-coated plates according to
manufacturer's recommendations (Charles River Labora-
tories, Wilmington, MA). These results were negative for
infection as previously included in our prior manuscript
[30]. In addition, we have tested our SeV stock for bacte-
rial contamination by streaking the viral stock on tryptic
soy agar plates supplemented with 5% sheep blood fol-
lowed by incubated for 48 hours at 37°C. No colonies
were identified. The Institutional Animal Use and Care
Committee of Washington University School of Medicine
approved all animal experiments.
Induction of viral bronchiolitis
SeV, a mouse parainfluenza type 1 virus that is similar to
the human paramyxoviruses (a class of viruses that
includes RSV, metapneumovirus, and parainfluenza
viruses) was used to generate airway inflammation of the
small airways (i.e., viral bronchiolitis) as we previously
described [29,31,32]. On day zero, seven-week-old
C57BL/6J female mice underwent anesthesia and intrana-
sal inoculation with SeV (Fushimi Strain, ATCC #VR-
105) at 5,000 egg infectious dose 50% (5 K). This dose
generates a sub-lethal tracheobronchitis/bronchiolitis
viral infection [31,32]. On days 8 and 21 post-inoculation,
the mice were anesthetized and euthanized for broncho-
alveolar lavage (BAL) fluid and lung tissue collection as
we previously described (see experiment design, Figure
1A) [29-33]. The day 8 time point corresponds to the
peak of acute airway inflammation, while the day 21 time
point corresponds to a chronic inflammatory phase of the
infection [29,31]. Each experiment was repeated 3 times
with multiple animals in each treatment group.
Azithromycin treatment
Mice were treated daily with subcutaneous azithromycin
(50 mg/kg dissolved in 100 μL sterile PBS, purchased
from Pfizer Pharmaceuticals, Dublin, Ireland), from day 0
(one hour after SeV inoculation) through day 7 post-viral
inoculation. Mice that were treated with subcutaneous
100 μL sterile PBS served as a control for the azithromy-
cin treatment. Azithromycin dose was determined based
on our previous pharmacokinetic studies [30] which
demonstrated that daily subcutaneous treatment of mice
with azithromycin (50 mg/kg) produced serum levels
similar to those observed in humans treated with the rec-
ommended azithromycin dose. Overall, a higher dosage
of azithromycin is required in mice than humans due to
more rapid liver metabolism in mice, resulting in an elim-
ination half-life of 2.3 hours compared to 68 hours in
humans [34,35].
Mouse specimen analyses
BAL and lung tissue harvest were performed as previ-
ously described [29-32]. Two blinded observers deter-
mined the BAL immune cell differential using standard
light microscopy criteria as described previously [30,31].
BAL inflammatory mediators were analyzed using a mul-
tiplex flow-cytometry based assay according to manufac-
turer's recommendations (Bio-Rad Laboratories) and as
previously described [30,31]. The detection limit for the
Bio-plex mouse cytokine 23-plex panel (Bio-Rad) is: IL-
1α - 2 pg/ml; IL-1β - 2 pg/ml; IL-2 - 3 pg/ml; IL-3 - 2 pg/
ml; IL-4 - 3 pg/ml; IL-5 - 2 pg/ml; IL-6 - 2 pg/ml; IL-9 - 15
pg/ml; IL-10 - 2 pg/ml; IL-12 (p40) - 2 pg/ml; IL-12 (p70)
- 4 pg/ml; IL-13 - 9 pg/ml; IL-17 - 1 pg/ml; eotaxin - 148
pg/ml; G-CSF - 1 pg/ml; GM-CSF - 7 pg/ml; IFN-γ - 6 pg/
ml; KC - 3 pg/ml; CCL2/JE - 14 pg/ml; CCL3/MIP-1β - 24
pg/ml; CCL4/MIP-1ί - 2 pg/ml; CCL5/RANTES - 5 pg/
ml; and TNF-α - 6 pg/ml.Beigelman et al. Respiratory Research 2010, 11:90
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Figure 1 Azithromycin attenuated viral-dependent weight loss. (A) Experiment time line. Seven-week-old C57BL/6J female mice were inoculat-
ed with Sendai virus 5,000 egg infectious dose 50% (SeV 5 K). Mice were treated daily with PBS or azithromycin day 0 (one hour after SeV inoculation) 
through day 7. On days 8 and 21, bronchoalveolar lavage (BAL) fluid and lungs and were harvested. (B) Percentage of weight change from baseline 
(day 0) in PBS (black square) versus azithromycin (black triangle) treated mice. Values are the mean ± SEM (n = 23 in each group). A significant decrease 
between PBS and azithromycin treatment is indicated (*, p < 0.05). (C) Kaplan-Meier analysis of survival. No statistical difference between treatment 
groups (n = 23 in each group) was determined by log-rank test.Beigelman et al. Respiratory Research 2010, 11:90
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Lung sections were stained with hematoxylin and eosin
(H&E) and Periodic Acid-Schiff (PAS) [30,31]. Quantifi-
cation of mucus producing cells was performed by count-
ing the number of airway cells that stained with PAS
positive cells and using a PAS score as previously
described [30,36,37]. Peripheral blood leukocyte counts
were performed using an automated veterinary hemato-
logic analyzer with a pre-programmed murine calibration
mode (Hemavet 950FS, Drew Scientific, Waterbury, CT)
as previously described [31].
PCR Quantification of Sendai virus
The quantity of Sendai virus-specific RNA was deter-
mined from whole lung using a TaqMan one-step fluoro-
genic RT-PCR reaction according to the manufacturer's
recommendation (Applied Biosystems, Foster City, CA)
[29,31]. Lung tissue was placed in RNA Later (Applied
Biosystems), homogenized with stainless steel beads for 3
min (Biospect Products Inc., Bartlesville, OK), and col-
umn purified with an RNeasy mini kit according to the
manufacturer's recommendations (Qiagen, Alencia, CA).
Duplicate serial 10-fold dilutions of total RNA from Sen-
dai-infected lung tissue underwent one-step fluorogenic
RT-PCR for detection of Sendai virus nucleocapsid pro-
tein transcripts (upstream primer 5'-TCCACCCTGAG-
GAGCAGG-3'; downstream primer 5'-ACCCGGCCAT
CGTGAACT-3'; probe 5'-6FAM-TGGCAGCAAAGCAA
AGGGTCTGGA-TAMRA-30) and murine GAPDH spe-
cific RNA (proprietary primer/probe combination,
Applied Biosystems; #MM99999915G1) to construct
standard curves. Sendai values were calculated as the
mean of duplicate samples from reactions with a cycle
threshold between 20 and 25 and final results were nor-
malized to GAPDH and reported as the Sendai/GAPDH
ratio.
Statistical analysis
Means from multiple groups (BAL cell counts and
i n f l a m m a t o ry  m e d i a t o r  c o n c e n t r a t i o n s  o n  d a y  8 )  w e r e
analyzed for statistical significance using a one-way anal-
ysis of variance (ANOVA) and post hoc comparison to
identify significant differences between specific groups.
An independent group's t-test was used to compare
means from two groups (BAL cell counts and inflamma-
tory mediator concentrations on day 21). The Mann-
Whitney test was used to compare the lung PAS scores
(an ordinal variable). The significance level for all tests
was 0.05. Data were analyzed using SPSS 15 software
(Chicago, IL).
Results
Azithromycin attenuated viral-dependent weight loss
To determine if azithromycin could confer anti-inflam-
matory properties in a mouse model of viral bronchioli-
tis, we inoculated mice on day 0 with SeV (5,000 egg
infectious dose 50%, 5 K) and treated the mice daily with
azithromycin or PBS from day 0 to day 7 (Figure 1A).
Mice treated with azithromycin had attenuated weight
loss compared to PBS treated mice, with significant dif-
ferences observed on days 3 through 9 post-inoculation
(Figure 1B). We noted a trend toward lower mortality in
the azithromycin treated mice (Figure 1C): 23/23 mice
survived in the azithromycin group versus 21/23 in the
control group (p = 0.12). To assess whether azithromycin
treatment would be beneficial using a higher infectious
dose, we performed an experiment using a lethal infec-
tious dose of virus (50,000 egg infectious dose 50%, 50 K).
Treatment of this lethal infection with azithromycin did
not significantly alter weight loss, overall survival or delay
the time of death compared to treatment with PBS (N = 5
in each cohort). These results demonstrated that azithro-
mycin treatment, in the 5 K infectious dose, attenuated
some clinical features of the severity of the acute viral
bronchiolitis. Therefore, we next sought to characterize
the impact of azithromycin treatment on lung inflamma-
tion.
Azithromycin attenuated viral-dependent airway 
inflammation
To determine whether azithromycin treatment could
attenuate airway inflammation during the SeV 5 K infec-
tion, we examined the lungs from PBS and azithromycin
treated mice 8 days following viral inoculation. This time
point correlates to peak post-viral airway inflammation
[31]. Compared to naive mice, SeV inoculated mice
treated with PBS had an accumulation of immune cells
predominantly in the peribronchial space, in the airway
lumen, and to a lesser extent in the alveolar spaces. In
some airways we observed severe epithelial cell injury
with disruption of the epithelial layer as described previ-
ously (Figure 2, middle panels) [38]. Treatment with
azithromycin attenuated the accumulation of inflamma-
tory cells in the lung tissue (Figure 2, right panels). To
quantify the accumulation of immune cells in the airways
we collected the BAL fluid. In agreement with the histo-
logic appearance of the lung tissue, azithromycin treat-
ment significantly attenuated the accumulation of total
BAL immune cells (Figure 3A). Analysis of the BAL leu-
kocyte populations demonstrated that azithromycin
treatment significantly decreased the accumulation of
macrophages, lymphocytes and neutrophils, with the
largest fold-reduction in the number of neutrophils (Fig-
ure 3B-D). To exclude the possibility that azithromycin
treatment decreased accumulation of immune cells in the
airways by a systemic depletion of immune cells, we
quantified total and differential leukocytes in the periph-
eral blood at day 8 post-viral inoculation. We observed no
significant differences between PBS and azithromycin-Beigelman et al. Respiratory Research 2010, 11:90
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treated cohorts, in terms of total leukocytes (mean cells/
μL ± SD, 4100 ± 1300 vs. 4000 ± 600 respectively; p =
0.81) or numbers of macrophages, lymphocytes or neu-
trophils (data not shown). Thus, azithromycin treatment
attenuated lung inflammation in this model of viral bron-
chiolitis.
Azithromycin attenuated viral-dependent airway 
inflammation is associated with decreased concentrations 
of BAL inflammatory mediators
Based on the observation that azithromycin treatment
decreased immune cell accumulation on day 8 post-inoc-
ulation, we proposed that azithromycin treatment would
also be associated with decreased concentration of BAL
inflammatory mediators. Compared to SeV inoculated
mice treated with PBS, treatment with azithromycin
attenuated the expression of multiple BAL chemokines
and growth factors (Figure 4A-D, column 2 versus 3).
Importantly, we observed a significant azithromycin-
dependent decrease in G-CSF and decreased concentra-
tions, albeit not statistically significant, of CCL2/JE,
CCL3/MIP-1α, CCL4/MIP-1β and CCL5/RANTES; all
these are proteins known to mediate viral immune
response (e.g., chemotaxis and activation of inflamma-
tory cells at site of inflammation). In addition, azithromy-
cin treatment resulted in trends toward lower
concentrations of multiple other inflammatory mediators
in the BAL (IL-1β, IL-5, IL-6, IL-9, IL-10, IL-12, GM-CSF
and IFN-γ), but had no effect on concentration of IL-17
and CXCL1/KC (data not shown). These data demon-
strate that azithromycin moderated the viral-dependent
secretion of multiple BAL mediators, several of which are
critical for chemotaxis and activation of inflammatory
cells.
Azithromycin modulation of viral-dependent airway 
inflammation is independent of Sendai viral load
To investigate whether azithromycin had an effect on SeV
burden in the lung tissue, we quantified SeV-specific
RNA at day 5 and 8 post-viral inoculation. These time
points were chosen based on our previous data that dem-
onstrated peak viral load in the lungs occurred on day 5
post-inoculation, and virus clearance on day 8 post-inoc-
ulation [31]. There were no differences in SeV-specific
RNA between PBS or azithromycin treated mice suggest-
ing azithromycin does not directly alter viral replication
or clearance (Figure 5). Thus, in this model of viral bron-
chiolitis, azithromycin anti-inflammatory properties are
independent of an anti-viral property.
Azithromycin treatment attenuated chronic viral-
dependent airway inflammation
As noted above, azithromycin treatment from day 0
through day 7 post-viral inoculation attenuated viral-
Figure 2 Azithromycin attenuated viral-dependent airway inflammation. Mice were inoculated with SeV and treated as in Figure 1. Eight days 
post-viral inoculation, lung sections were obtained from naive mice (Naive, left column); SeV infected mice treated with PBS (SeV + PBS, middle col-
umn), and SeV infected mice treated with azithromycin (SeV + Azithro, right column). Representative photomicrographs of hematoxylin and eosin 
stained lung sections are shown (n = 11, Azithro; n = 12, PBS). Inflammatory cells within the airway are indicated (arrow). Bar = 50 μm (top) and 25 μm 
(bottom).Beigelman et al. Respiratory Research 2010, 11:90
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Figure 3 Azithromycin attenuated viral-dependent accumulation of total cells, macrophages, lymphocytes and neutrophils in the BAL. BAL 
from mice treated as in Figure 1 was analyzed for total and differential cell number eight days post-inoculation. Groups are labeled as in Figure 2A and 
values are the mean ± SEM (n = 11, Azithro; n = 12, PBS) of total BAL cells (A), macrophages (B), lymphocytes (C) and neutrophils (D). A significant 
decrease between PBS and azithromycin treatment is indicated (*, p < 0.05).Beigelman et al. Respiratory Research 2010, 11:90
http://respiratory-research.com/content/11/1/90
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Figure 4 Azithromycin attenuated viral-dependent airway inflammation is associated with decreased concentrations of BAL inflammatory 
mediators. BAL from mice treated as in Figure 1 was analyzed for inflammatory mediators eight days post-inoculation. Concentrations of inflamma-
tory mediators in the cell-free BAL supernatant were determined using a multiplex flow-cytometry based assay (Bio-Rad Laboratories). Groups are la-
beled as in Figure 2B and values are the mean ± SEM (n = 11, Azithro; n = 12, PBS) of G-CSF (A), CCL2/JE (B), CCL4/MIP-1β (C), CCL5/RANTES (D). A 
significant decrease between PBS and azithromycin treatment is indicated (*, p < 0.05).Beigelman et al. Respiratory Research 2010, 11:90
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dependent airway inflammation at day 8 (peak of inflam-
mation). Next we investigated whether azithromycin
would also modify the chronic inflammatory phase of the
infection. On day 21 post-viral inoculation, the accumu-
lation of total BAL immune cells was elevated compared
to naive mice. There were fewer total cells (although not
statistically significant) in the BAL of the azithromycin
treated cohort compared to those treated with PBS (Fig-
ure 6A). There was a trend toward fewer BAL neutrophils
in the azithromycin treated mice (Figure 6B). Moreover,
azithromycin treatment resulted in a significant decrease
in the BAL concentrations of G-CSF and CXCL1/KC
(Figure 6C-D), and in a trend toward a decreased concen-
tration of CCL2/JE (data not shown). No statistical differ-
ence was noted between the azithromycin and PBS
treated mice in terms of the extent of mucous cell meta-
plasia (PAS score 1.1 vs. 1.0 respectively; p = 0.58). These
results demonstrated that azithromycin treatment altered
not only acute airway inflammation, but modified certain
key aspects of the chronic inflammatory phase of the
infection.
Discussion
This study demonstrated that azithromycin possessed
beneficial anti-inflammatory properties in a mouse
model of paramyxoviral bronchiolitis. Azithromycin
treatment improved the course of acute disease, evi-
denced by decreased weight loss and attenuated accumu-
lation of BAL inflammatory cells and chemokines.
Although not statistically significant, we noted a trend
toward lower mortality in the azithromycin treated mice.
We also observed that early azithromycin treatment was
associated with modulation of certain features of the
chronic post-viral inflammatory phase. To the best of our
knowledge, this is the first study to demonstrate the ben-
eficial effects of azithromycin in a mouse model of viral
bronchiolitis and suggests this drug may also have benefi-
cial effects in human bronchiolitis.
Our results are in agreement with a previous study by
Sato and colleagues, who investigated the effect of eryth-
romycin treatment using an in vivo model of influenza
pneumonia [39]. That study showed that erythromycin
treatment in mice resulted in improved survival,
decreased weight loss, and attenuated airway inflamma-
tion. Our results extend those findings by demonstrating
that a clinically better tolerated macrolide displayed anti-
inflammatory properties in a different viral infection
model (i.e., a parainfluenza viral bronchiolitis vs. influ-
enza pneumonia). In addition, we demonstrated that
treatment of the acute inflammation is associated with
attenuation of the chronic post-viral inflammatory phase.
Our results revealed that azithromycin had no effect on
SeV viral kinetics in the lung tissue at day 5 and 8 post-
viral inoculation, time points that corresponded to the
peak of viral load in the lungs and virus clearance respec-
tively [31]. Accordingly, in this case we conclude that
azithromycin has anti-inflammatory, but no direct in vivo
anti-viral properties. This observation agrees with the
previously mentioned report, in which erythromycin
treatment did not alter influenza viral kinetics [39].
Although weight loss is attenuated and viral clearance is
not compromised by treatment with azithromycin, it
remains unclear how azithromycin or other macrolides
would alter additional clinical outcomes of a human viral
infection such as nasal congestion, nasal discharge, and
cough as we have not developed techniques to quantitate
these in the mouse. We do note that a recent study found
that macrolide antibiotics inhibited RSV infection in iso-
lated human tracheal epithelial cells [40]. These appar-
ently conflicting results could be related to differences
between in vivo and in vitro viral infection models, use of
different paramyxoviruses, or to different dosing regi-
mens and pharmacologic properties of the drugs.
During the peak inflammatory response, azithromycin
treatment attenuated cellular influx in the lung tissue and
BAL. Decreased cellular influx in site of inflammation is
consistent with previous reports in other inflammatory
models in which macrolides attenuated neutrophilic
inflammation induced by inhaled LPS [41,42] or intratra-
cheal P. aeruginosa infection [43]. The effect of azithro-
mycin, in our viral bronchiolitis model, does not appear
to be neutrophil-specific since the accumulation of mac-
Figure 5 Azithromycin attenuated viral-dependent airway in-
flammation is independent of Sendai virus load. Mice were inocu-
lated with SeV and treated as in Figure 1. Five and eight days post-
inoculation, whole-lung RNA was analyzed for Sendai virus-specific 
and GAPDH RNA by one-step fluorogenic reverse transcriptase-poly-
merase chain reaction (RT-PCR). The mean of duplicate measurements 
of SeV-specific RNA was normalized to GAPDH and reported as the SeV 
to GAPDH ratio. Values are the mean ± SEM (n = 6, day 5; n = 4, day 8).Beigelman et al. Respiratory Research 2010, 11:90
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rophages and lymphocytes were also attenuated. In previ-
ous work, we demonstrated that azithromycin had the
most profound effect on eosinophils in an in vivo allergic
model of airway inflammation [30]. Taken together, these
observations suggest that macrolides possess broad anti-
inflammatory properties that can attenuate the accumu-
lation of multiple cell types in various airway inflamma-
tory models.
One limitation of this study is the initiation of azithro-
mycin treatment on the day of infection. Another limita-
t i o n  i s  t h a t  w e  d i d  n o t  t e s t  f o r  a  b e n e f i c i a l  t r e a t m e n t
effect of azithromycin on other respiratory viruses, such
as RSV. RSV is a human pathogen and in our experience
RSV infection of mice results in pneumonia rather then
bronchiolitis. We have found that SeV replicates at high
efficiency in the mouse lung and results in acute inflam-
mation of the small airways (i.e., bronchiolitis) that better
mimics human bronchiolitis. Since we have not tested for
a beneficial treatment effect of azithromycin on RSV
infection it is difficult to compare our results to previous
studies that modulated the host immune response by
blocking the CX3C chemokine activity of the G protein of
RSV [44-46]. Future studies will be required to determine
if different treatment regimens, such as initiation of treat-
ment a few days after inoculation or alternate dosing reg-
imens would result in a similar beneficial treatment effect
on SeV as well as other respiratory viruses.
Although the precise biochemical mechanisms respon-
sible for the anti-inflammatory effects of macrolides are
not defined, this family of drugs can inhibit multiple cel-
lular processes involved in an inflammatory response. For
example, macrolides have been shown to inhibit neutro-
phil chemotaxis, leukocyte-epithelial cell adhesion,
cytokine secretion and cytokine-dependent intracellular
signaling [43,47]. In this regard, macrolides block NF-κB
and AP-1 dependent gene transcription of inflammatory
mediators [42,48,49]. Thus, additional studies will be
required to further define the precise cellular mecha-
nisms responsible for the anti-inflammatory effects of
azithromycin and to determine the optimal dosing regi-
mens required to attenuate both the acute and chronic
post-viral inflammatory phenotypes.
Previous clinical studies have shown that macrolides
are beneficial in the treatment of inflammatory airway
diseases such as diffuse panbronchiolitis [13], cystic
fibrosis [14], and asthma [15-25]. Two previous studies
investigated the effects of macrolide treatment in chil-
dren hospitalized with RSV bronchiolitis [26,27]. Tahan
et al. [27] revealed that a 21 day course of clarithromycin
treatment reduced length of hospital stay, the duration of
additional treatments (supplemental oxygen, intravenous
fluids and bronchodilators) and the day 21 concentra-
tions of IL-4, IL-8 and eotaxin in the serum. However,
this study was limited by a relatively small sample size (n
= 21). In a recent larger study, Kneyber et al. found that
azithromycin treatment did not improve the early disease
course in infants hospitalized with RSV bronchiolitis
[26]. This study, although important, had two main limi-
tations that may have obscured any potential benefits of
the macrolide. First, the researchers designed an equiva-
lence study based on the assumption that a difference less
than ± 49.4 hours (approximately ± 2 days) in length of
Figure 6 Azithromycin treatment attenuated chronic viral-dependent airway inflammation. Mice were inoculated with SeV and treated as in 
Figure 1. Twenty-one days post-inoculation, lung sections and BAL fluid were harvested. Values are the mean ± SEM (n = 10, Azithro; n = 8, PBS) of 
total BAL cells (A), macrophages, lymphocytes and neutrophils in the BAL (B), and concentrations of the chemokines: G-CSF (C) and CCL1/KC (D). A 
significant decrease between PBS and azithromycin treated mice is indicated (*, p < 0.05).Beigelman et al. Respiratory Research 2010, 11:90
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hospitalization would be considered as equivalence (i.e.,
no benefit for treatment). Therefore, this study was not
powered to detect smaller differences in length of hospi-
talization. Second, the researchers recruited only 71% of
the required study population that was determined based
on their power analysis. This early termination of the trial
prevents definitive conclusions.
The current study highlights the importance of mea-
suring macrolide-dependent effects during the early
phase of the viral infection as well as the late phase. In
addition we have identified certain growth factors and
chemokines (i.e., G-CSF, CCL2, CCL4, CCL5, and
CXCL1) that could be tracked to establish a beneficial
treatment effect. Accordingly, when planning a human
study we feel early and long-term follow-up of clinical
and biochemical endpoints should be included in the
study design.
Our study revealed that treatment of mouse SeV bron-
chiolitis with azithromycin during the acute infection
would attenuate acute and chronic airway inflammation,
and also decrease the chronic post-viral pathologic
abnormalities. However, we do not recommend the off-
label use of azithromycin during RSV infection until
additional prospective randomized clinical trials support
its use since excessive use of macrolides has correlated
with increased prevalence of macrolide-resistant organ-
isms such as Streptococcus pneumonia [50].
Conclusions
Our results extend previous findings obtained in different
in vivo models by demonstrating that azithromycin pos-
sessed anti-inflammatory properties in an in vivo model
of viral bronchiolitis. We found that early treatment dur-
ing viral infection is associated with attenuation of acute
and chronic airway inflammation. Azithromycin treat-
ment improved the course of acute disease, evidenced by
decreased weight loss and attenuated accumulation of
BAL inflammatory cells and chemokines. Our data
revealed that early azithromycin treatment also modu-
lates the chronic post-viral inflammatory phase. These
results support the rationale for future prospective ran-
domized clinical trials that will evaluate the effects of
macrolides on acute viral bronchiolitis and their long-
term consequences.
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